RONALD T. MITSUYASU, M.D.; RICHARD E. CHAMPLIN, M.D.; ROBERT PETER GALE, M.D., Ph.D.; WINSTON G. HO, M.D.; CARL LENARSKY, M.D.; DREW WINSTON, M.D.; MICHAEL SELCH, M.D.; ROBERT ELASHOFF, Ph.D.; JANIS V. GIORGI, Ph.D.; JOHN WELLS, Ph.D.; PAUL TERASAKI, Ph.D.; RONALD BILLING, Ph.D.; STEPHEN FEIG, M.D.
The effects of ex-vivo depletion of T lymphocytes from donor bone marrow using a monoclonal anti-T-cell antibody (CT-2) and complement on the outcome of allogeneic bone marrow transplantation was evaluated in a prospective, randomized, double-blind study of 40 patients with leukemia. Patients receiving T-cell-depleted bone marrow had a lower incidence of acute graft-versus-host disease than control patients (3 of 20 compared with 13 of 20; p = 0.004), and mortality due to acute graft-versus-host disease was reduced. Five patients in the T-cell-depletion group developed graft failure; all control patients had sustained engraftment (p < 0.05). Clinically apparent relapse of leukemia occurred in 7 patients from the T-cell-depletion group and in 2 controls (p, not significant). Cytogenetic evidence of residual leukemia was also detected in the 5 patients with graft failure without overt relapse. Infections and overall survival were similar in the two groups. The effects of T-cell depletion on engraftment and recurrence of leukemia require further evaluation.
MITSUYASU RT, CHAMPLIN RE, GALE RP, HO WG, LENARSKY C, WINSTON D, et al. Treatment of Donor Bone Marrow with Monoclonal Anti-T-Cell Antibody and Complement for the Prevention of Graft-Versus-Host Disease: A Prospective, Randomized, Double-Blind Trial. Ann Intern Med. ;105:20–26. doi: 10.7326/0003-4819-105-1-20
Download citation file:
Published: Ann Intern Med. 1986;105(1):20-26.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use